Preliminary, positive safety and efficacy results from the first patient dosed in the Phase 1/2 CHORD trial investigating otoferlin gene therapy.
Regeneron announced preliminary, positive safety and efficacy results from the first patient (<2 years of age) dosed in the Phase 1/2 CHORD trial investigating otoferlin gene therapy (DB-OTO) in children with profound genetic hearing loss due to mutations of the…